Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anaplastic Lymphoma Kinase”

151 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 151 results

Large-scale testing (Phase 3)Study completedNCT02604342
What this trial is testing

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Who this might be right for
Non-small Cell Lung Cancer
Hoffmann-La Roche 119
Early research (Phase 1)Study completedNCT01567709
What this trial is testing

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

Who this might be right for
Adult B Acute Lymphoblastic LeukemiaAdult T Acute Lymphoblastic LeukemiaAnaplastic Large Cell Lymphoma+32 more
National Cancer Institute (NCI) 34
Not applicableLooking for participantsNCT05122806
What this trial is testing

Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

Who this might be right for
Non-small Cell Lung CancerALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie 100
Large-scale testing (Phase 3)Looking for participantsNCT05722886
What this trial is testing

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Who this might be right for
Haematological MalignancySolid Tumour
Cancer Research UK 825
Early research (Phase 1)Active Not RecruitingNCT02321501
What this trial is testing

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+3 more
M.D. Anderson Cancer Center 37
Not applicableStudy completedNCT04087473
What this trial is testing

Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

Who this might be right for
Non-small Cell Lung CancerALK-Positive Lung Cancer
National Cancer Centre, Singapore 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT05200481
What this trial is testing

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Who this might be right for
Non Small Cell Lung CancerALK Gene Mutation
Intergroupe Francophone de Cancerologie Thoracique 110
Testing effectiveness (Phase 2)UnknownNCT04056572
What this trial is testing

Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Who this might be right for
ALK-positive NSCLC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 135
Testing effectiveness (Phase 2)Ended earlyNCT02846792
What this trial is testing

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Who this might be right for
ALK Gene TranslocationEGFR Activating MutationRecurrent Non-Small Cell Lung Carcinoma+3 more
University of Washington 5
Early research (Phase 1)Study completedNCT01401504
What this trial is testing

Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors

Who this might be right for
Solid Tumor
Astellas Pharma Inc 29
Early research (Phase 1)Looking for participantsNCT07001384
What this trial is testing

Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Who this might be right for
Anaplastic Lymphoma KinaseAnaplastic Large Cell Lymphoma
Memorial Sloan Kettering Cancer Center 30
Large-scale testing (Phase 3)Study completedNCT03194893
What this trial is testing

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Who this might be right for
Neoplasms
Hoffmann-La Roche 50
Testing effectiveness (Phase 2)Study completedNCT02094573
What this trial is testing

Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Ariad Pharmaceuticals 222
Early research (Phase 1)UnknownNCT04671849
What this trial is testing

An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.

Who this might be right for
Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion
Jiangsu Simcere Pharmaceutical Co., Ltd. 243
Testing effectiveness (Phase 2)UnknownNCT05869162
What this trial is testing

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

Who this might be right for
Non-small-cell Lung Carcinoma
Shouyao Holdings (Beijing) Co. LTD 153
Testing effectiveness (Phase 2)Looking for participantsNCT04322890
What this trial is testing

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationALK Gene Mutation+2 more
Hunan Province Tumor Hospital 6,000
Testing effectiveness (Phase 2)Study completedNCT03155009
What this trial is testing

The Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 44
Not applicableLooking for participantsNCT05724004
What this trial is testing

Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)

Who this might be right for
Radiotherapy Side EffectNon-small Cell Lung CancerALK Gene Mutation
Karolinska University Hospital 70
Post-approval studies (Phase 4)Looking for participantsNCT05525338
What this trial is testing

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels

Who this might be right for
Drug MonitoringCarcinoma, Non-Small-Cell LungLung Cancer+2 more
University Medical Center Groningen 196
Post-approval studies (Phase 4)Ended earlyNCT03672643
What this trial is testing

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Who this might be right for
ALK or ROS1-positive NSCLC
Pfizer 41
Next Page